4/A//SEC Filing
PDL BIOPHARMA, INC. 4/A
Accession 0000882104-16-000090
CIK 0000882104operating
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 6:38 PM ET
Size
5.3 KB
Accession
0000882104-16-000090
Insider Transaction Report
Form 4/AAmended
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Common stock
2014-04-10$8.22/sh+30,693$252,296→ 86,048 total
Footnotes (2)
- [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved,based upon the following schedule: 50% on December 12, 2015; 16.66% on December 12, 2016; 16.66% on December 12, 2017; and 16.66% on December 12, 2018.
- [F2]The amount of securities beneficially owned following the transaction above is being amended to remove 21,315 shares which were incorrectly reported as being beneficially owned by Mr. Stone.
Documents
Issuer
PDL BIOPHARMA, INC.
CIK 0000882104
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000882104
Filing Metadata
- Form type
- 4/A
- Filed
- Jan 27, 7:00 PM ET
- Accepted
- Jan 28, 6:38 PM ET
- Size
- 5.3 KB